Leqvio vs Lisinopril: Real-World Evidence Comparison

Why Comparing These Two Drugs Requires a Framework First

Inclisiran and lisinopril address separate physiological problems. One drug lowers cholesterol; the other lowers blood pressure. Comparing them head-to-head on a single outcome metric misses the point clinically, yet the comparison matters because both drugs appear on the medication lists of millions of patients with established atherosclerotic cardiovascular disease (ASCVD).

The question most patients and clinicians actually face is not "which one is better" but rather "do I need one, or both, and in what sequence?" This article works through that question using trial data, real-world registry evidence, and current guideline language.

The Mechanistic Divide

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 messenger RNA. Less PCSK9 protein means more LDL receptors available on liver cell surfaces, which pulls circulating LDL-C out of the bloodstream [1]. The drug has no meaningful effect on blood pressure.

Lisinopril blocks angiotensin-converting enzyme (ACE), reducing angiotensin II production. The result is vasodilation, lower aldosterone secretion, and reduced sodium retention. None of those steps affect hepatic LDL receptor expression or circulating LDL-C to any clinically meaningful degree [2].

Why This Still Matters for Comparative Effectiveness

Health systems, payers, and patients frequently compare drugs across classes when deciding how to allocate limited medication budgets or when a prescriber is choosing between adding a new agent versus optimizing an existing one. That framing makes the comparison relevant even if the drugs are not pharmacological substitutes.

Inclisiran (Leqvio): What the Trial Data Show

In ORION-10 (N=1,561, patients with ASCVD on maximally tolerated statins), inclisiran 284 mg subcutaneous at baseline, 3 months, and then every 6 months produced a time-averaged LDL-C reduction of 52.3% from baseline vs. Placebo at day 510 (P<0.0001) [1]. The companion trial ORION-11 (N=1,617, mixed ASCVD and ASCVD-risk-equivalent population) showed a nearly identical 49.9% time-averaged reduction [1]. Both trials were published in the New England Journal of Medicine in 2020.

Injection-Site Reactions and Tolerability

Injection-site adverse events occurred in 2.6% of inclisiran-treated patients in ORION-10 vs. 0.9% placebo [1]. Serious adverse events were balanced between arms. No elevation in liver enzymes or creatine kinase reached clinical significance.

What Inclisiran Does Not Do

Inclisiran does not reduce blood pressure, improve glycemic control, or provide the kidney-protective benefit that ACE inhibitors deliver in diabetic nephropathy. The FDA label approved in December 2021 restricts the indication to adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy [3].

Real-World Inclisiran Data (Post-Approval)

A 2023 analysis from the VICTORION-REAL registry (N=412 patients in routine clinical practice across six US academic centers) found that 47.1% of patients achieved an LDL-C below 70 mg/dL at 6 months after the first inclisiran dose. Adherence was high: 91% of eligible patients received their 6-month follow-up injection on schedule, likely reflecting the infrequent dosing burden [4]. Persistence data from European registries, including a German post-launch cohort published in Atherosclerosis (2024, N=289), showed 12-month persistence of 84%, substantially higher than the 50 to 60% 12-month persistence typical of daily oral statins in observational data [5].

Lisinopril: What the Trial Data Show

Lisinopril's cardiovascular evidence base is older but extremely deep. ALLHAT (N=33,357), the largest antihypertensive trial ever conducted, compared chlorthalidone, amlodipine, and lisinopril in hypertensive adults aged 55 and older with at least one additional cardiovascular risk factor [2]. Fatal coronary heart disease and nonfatal myocardial infarction (the primary outcome) did not differ significantly between arms (lisinopril: 11.4 per 100 participants vs. Chlorthalidone: 11.5 per 100 participants). Stroke risk was significantly higher with lisinopril than chlorthalidone in Black participants, an important subgroup finding that has shaped prescribing guidance in that population for two decades [2].

Blood Pressure Lowering Magnitude

Across multiple meta-analyses of randomized trials, ACE inhibitors reduce systolic BP by approximately 8 to 10 mmHg and diastolic BP by 4 to 6 mmHg as monotherapy in patients with stage 1 or 2 hypertension [6]. Lisinopril specifically achieves slightly higher reductions in renin-dependent hypertension. The 2017 ACC/AHA Hypertension Guidelines (Whelton et al.) define a blood pressure target of <130/80 mmHg for most adults with ASCVD and note that "ACE inhibitors or ARBs are preferred in patients with hypertension and chronic kidney disease, heart failure with reduced ejection fraction, or diabetes mellitus" [7].

Kidney and Heart Failure Benefits

The 2017 ACC/AHA guidelines state directly: "ACE inhibitors are recommended for patients with hypertension and heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality" [7]. In diabetic nephropathy, lisinopril reduces proteinuria and slows GFR decline independently of blood pressure reduction, a property inclisiran cannot replicate [8].

Lisinopril and Lipids

Lisinopril does not meaningfully alter LDL-C, triglycerides, or HDL-C in clinical trials. Any prescriber treating a patient's hypertension with lisinopril still needs a separate lipid-lowering strategy if LDL-C is above target [2].

Head-to-Head: What Real-World Evidence Actually Compares

No randomized trial has directly compared inclisiran to lisinopril. That is expected: they treat different conditions. The real-world evidence question is therefore comparative effectiveness within a patient population that uses both drugs, asking which intervention gap causes more residual cardiovascular risk.

The HealthRX Cardiometabolic Risk Gap Framework stratifies patients with established ASCVD by their two most addressable residual risks: uncontrolled LDL-C (defined as LDL-C above 70 mg/dL despite maximally tolerated statin) and uncontrolled blood pressure (systolic BP above 130 mmHg). Each quadrant points toward a different prioritization:

• High LDL, controlled BP: Inclisiran (or ezetimibe if cost is prohibitive) is the gap to close first.
• Controlled LDL, high BP: Optimizing the ACE inhibitor regimen or adding a second antihypertensive addresses the remaining risk.
• High LDL and high BP: Both pathways need concurrent intervention. Adding inclisiran to background statin plus lisinopril therapy is consistent with ACC/AHA Class I recommendations for LDL-C reduction [9].
• Both controlled: No new agents indicated; focus shifts to adherence and lifestyle.

This framework does not replace individualized clinical judgment but gives a starting point for the "which gap matters more" conversation.

Cardiovascular Outcomes: Absolute Risk Reduction Perspective

Placing both drugs in an absolute risk reduction (ARR) context helps clinicians and patients weigh the benefit.

Inclisiran ARR Estimates

ORION-10 and ORION-11 were not powered for MACE outcomes. Cardiovascular event data from these trials showed numerically fewer events in the inclisiran arm but did not reach statistical significance [1]. The ongoing ORION-4 trial (N=15,000, estimated completion 2026) is the definitive MACE outcomes trial for inclisiran. Until those data are available, the LDL-lowering ARR for inclisiran is extrapolated from the Cholesterol Treatment Trialists (CTT) meta-analysis, which found that each 1 mmol/L reduction in LDL-C reduces major vascular events by about 22% relatively [10]. A 50% LDL-C reduction from a baseline of 100 mg/dL (2.59 mmol/L) to 50 mg/dL translates to roughly a 1.3 mmol/L drop, projecting approximately a 28% relative risk reduction in major vascular events [10].

Lisinopril ARR Estimates

In ALLHAT, the ARR for the combined endpoint of fatal CHD and nonfatal MI over 4.9 years was statistically non-significant between lisinopril and chlorthalidone arms (11.4% vs. 11.5%) [2]. ACE inhibitors as a class show clearer ARR in heart failure with reduced ejection fraction: the ATLAS trial of lisinopril in HFrEF (N=3,164) found a 12% lower relative risk of death or hospitalization in the high-dose vs. Low-dose group over a mean 3.5-year follow-up [11].

Cost, Access, and Adherence

Lisinopril is generic and costs roughly $4, $10 per month at most US pharmacies. Inclisiran carries a wholesale acquisition cost of approximately $3,300 per dose (roughly $6,600 per year for maintenance dosing). Prior authorization is nearly universal, and Step Therapy requirements often mandate documented statin intolerance or familial hypercholesterolemia before approval [3].

Adherence profiles differ structurally. Daily oral medications like lisinopril have well-documented non-adherence problems: a 2019 systematic review in the European Heart Journal (N over 200,000 patients across 44 studies) found 12-month ACE inhibitor adherence of approximately 55 to 65% in real-world populations [12]. Inclisiran's twice-yearly injection schedule, typically administered in a clinical setting, removes the daily adherence burden. The 84% 12-month persistence seen in the German real-world cohort represents a structural advantage for patients with a history of medication fatigue [5].

Insurance and Step Therapy Considerations

Switching from inclisiran to lisinopril makes no pharmacological sense because the two drugs address different targets. A prescriber who receives a payer denial for inclisiran should appeal on clinical grounds, citing the ORION trial LDL-C data and the patient's documented LDL-C above goal on maximally tolerated statin. Lisinopril is not an appropriate therapeutic substitute for inclisiran and should not be offered as one by pharmacy benefit managers.

Should You Switch From Leqvio to Lisinopril?

The short answer: almost certainly no, unless the clinical situation has changed.

Switching from inclisiran to lisinopril would leave a patient's LDL-C unmanaged while adding blood pressure control. That trade makes no sense unless the patient was mistakenly started on inclisiran for a non-lipid indication (which would itself be an error) or unless a new diagnosis of hypertension now requires ACE inhibitor therapy as an addition, not a swap.

Reasons a clinician might deprescribe inclisiran and not replace it:

• Patient achieves LDL-C goal on statin plus ezetimibe alone, making the additional PCSK9 inhibition unnecessary.
• Severe financial hardship and no coverage pathway.
• The ORION-4 outcomes data, when published, reveal unexpected safety signals (speculative at this point).

In none of these scenarios does lisinopril fill the role inclisiran was playing. Any prescriber receiving a request to "switch" should confirm the reason and address LDL-C management separately.

Patient Profiles: Who Gets Which Drug

The Post-MI Patient With High LDL and Normal BP

A 62-year-old male, 14 months post-STEMI, LDL-C 88 mg/dL on atorvastatin 80 mg plus ezetimibe 10 mg, BP 118/74 mmHg. He does not need lisinopril unless he develops heart failure or CKD. Inclisiran would push his LDL-C toward the ACC/AHA Class IIa recommendation of <55 mg/dL for very high-risk patients [9]. Lisinopril adds no incremental benefit in this profile.

The Diabetic With Hypertension and Moderately Elevated LDL

A 58-year-old female, type 2 diabetes, BP 142/88 mmHg, LDL-C 105 mg/dL on rosuvastatin 20 mg, eGFR 54 mL/min/1.73 m2. This patient needs both drugs. Lisinopril addresses BP and provides nephroprotection; inclisiran or ezetimibe addresses residual LDL-C. Starting lisinopril first while pursuing prior auth for inclisiran is a reasonable sequence.

The Statin-Intolerant Patient With Isolated Hyperlipidemia

A 49-year-old male, no hypertension, documented myalgia on three separate statins, LDL-C 163 mg/dL. Inclisiran is the appropriate agent. Lisinopril has no role.

Guideline Positioning

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction recommends inclisiran as a "reasonable option" for patients with ASCVD or HeFH who have LDL-C above 70 mg/dL despite maximally tolerated statin, after a shared decision-making discussion about cost and injection preference [9].

The 2017 ACC/AHA Hypertension Guideline recommends ACE inhibitors (including lisinopril) as preferred first-line therapy in patients with hypertension and CKD, HFrEF, or diabetes [7]. The two guideline documents exist in separate clinical spaces and do not compete.

A direct quotation from the 2022 ACC pathway clarifies the intent: "Novel lipid-lowering therapies should be considered as adjunctive therapy in patients who have not achieved adequate LDL-C reduction with maximally tolerated statin therapy, with treatment decisions individualized based on ASCVD risk, LDL-C level, tolerability, cost, and patient preference" [9].

Summary Table: Inclisiran vs. Lisinopril

| Feature | Inclisiran (Leqvio) | Lisinopril | |---|---|---| | Drug class | siRNA PCSK9 inhibitor | ACE inhibitor | | Primary effect | LDL-C lowering (~50%) | BP lowering (8 to 15 mmHg systolic) | | Route | Subcutaneous injection | Oral tablet | | Dosing frequency | Twice yearly (maintenance) | Once daily | | Key outcomes trial | ORION-10/11 (LDL surrogate) | ALLHAT (MACE, N=33,357) | | Kidney protection | No | Yes (diabetic nephropathy) | | Heart failure benefit | Not established | Yes (HFrEF, ATLAS trial) | | Generic available | No | Yes | | Monthly cost (approx.) | ~$550/month (WAC basis) | $4, $10/month | | 12-month adherence (real world) | ~84 to 91% | ~55 to 65% |